Anondita Medicare MD, chairman, board of directors and AGM
NSE: ANONDITAPersonal Products
Share price at the NSE close on 23 Oct 2026. Previous close ₹980.45.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹1,888 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 29 May 2026
- 55.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 29 May 2026
- 26.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.26
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 92,60067.0% delivered
Anondita Medicare board of directors
At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- Jain Chopra and CompanyPeer-review certificate valid to Mar 2029
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Anondita Medicare AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Anondita Medicare share news and announcements
Annual general meeting, 29 Sep 2026
1,968 shareholders on the register on 22 Sep 2026; present: 4 promoters and 17 others; votes counted by MOHIT SINGHL AND ASSOCIATES / MOHIT SINGHAL.The company's voting result (opens in a new tab)
To consider and adopt the audited standalone and consolidated financial statements of the company for the financial year ended 31st March 2026, together with the reports of the board of directors and auditors thereon.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 63.27% · promoters 99.66% · institutions 0.00% · other public 3.54%
To appoint a director in the place of Mr. Lakhinder Singh (DIN: 07703780) who retires by rotation in terms of section 152(6) of the Companies Act, 2013, and being eligible, offers himself for re-appointmentMoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 63.27% · promoters 99.66% · institutions 0.00% · other public 3.54%
- To ratify the remuneration of cost auditors for the financial year ending 31st march 2027Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 63.27% · promoters 99.66% · institutions 0.00% · other public 3.54%
- Approval for material modification of earlier approved material related party transaction(s) with Anondita Healthcare & Rubber Products India limited (“AHRPIL”/ “subsidiary”):OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 1.08% · promoters 0.00% · institutions 0.00% · other public 3.54%
- Approval of material modification of earlier approved material related party transaction(s) with Mr. Anupam Ghosh, promoter and managing director of the company:OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 1.08% · promoters 0.00% · institutions 0.00% · other public 3.54%
- Approval for material related party transaction(s) between Anondita Healthcare & Rubber Products India limited, subsidiary company with Anondita healthcare (partnership firm)OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 1.08% · promoters 0.00% · institutions 0.00% · other public 3.54%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Extraordinary general meeting, 28 May 2026, 7 resolutions
682 shareholders on the register on 21 May 2026; present: 4 promoters and 15 others; votes counted by MOHIT SINGHAL / MOHIT SINGHAL & ASSOCIATES.The company's voting result (opens in a new tab)
- Issue of warrants, convertible into equity shares to person(s) belonging to promoter category and to person(s) belonging to promoter category on preferential basis.SpecialPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 62.88% · promoters 99.73% · institutions 0.00% · other public 2.22%
- Approval for material Related Party Transaction(S) with Anondita Healthcare & Rubber Products (India) Limited for the financial year 2026-27OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 0.64% · promoters 0.00% · institutions 0.00% · other public 2.22%
- Approval for material Related Party Transaction(S) with Anupam Gosh for the financial year 2026-27.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 0.64% · promoters 0.00% · institutions 7.36% · other public 0.00%
- To ratify the material Related Party Transaction held with M/s Anondita Healthcare and Rubber Products (India) Ltd.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 0.64% · promoters 0.00% · institutions 0.00% · other public 2.22%
- Amendment in the main object clause of the Memorandum of Association of the Company.Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 62.88% · promoters 99.73% · institutions 0.00% · other public 2.22%
- Increase in managerial remuneration of Mr. Reshant Ghosh, Whole Time Director of the company.SpecialPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 62.88% · promoters 99.73% · institutions 0.00% · other public 2.22%
- Increase in managerial remuneration of Mr. Anupam Ghosh, Managing Director of the Company.SpecialPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 62.88% · promoters 99.73% · institutions 0.00% · other public 2.22%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Mar 2026.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere | Reason and comments |
|---|---|---|---|---|---|---|
| Public IssuesAug 2025, checked by Infomerics Valuation and Rating Limited | 69.49 | Capex | 6.00 | 2.62 | Yes | As disclosed in the Prospectus dated 28 August 2025, the original objects of the issue were Capital Expenditure (CAPEX), Funding Working Capital Requirements, General Corporate Purposes (GCP) and Unidentified Acquisition. During the quarter ended September 30 2025 andDecember31 2025 and March 31, 2026, certain modifications and reallocations were made in the utilization of IPO proceeds. Subsequently, the shareholders approved and ratified the revised utilization and reallocation of funds through a Special Resolution passed at the Extra-Ordinary General Meeting of the Members held on 12 February 2026. Accordingly: • An amount of ₹278.41 lakhs was reallocated from General Corporate Purposes to Funding Working Capital Requirements, resulting in the revised allocation for working capital requirements increasing from ₹3500 Lakhs to ₹3778.41Lakhs. • The allocation towards General Corporate Purposes and Unidentified Acquisitionwas revised from ₹2015.87 Lakhs to ₹1737.46Lakhs and shall now be utilized only towards General Corporate Purposes within the revised regulatory limits. No unidentified acquisition shall be undertaken using the IPO proceeds. • • The Company has also revised the deployment timeline of funds under General Corporate Purposes. The entire balance amount was originally expected to be utilized within FY 2025–26; however, the remaining balance of Rs. 123.25 Lakhs shall now be utilized during FY 2026–27. • Further, the utilization towards working capital requirements increased due to expansion in the scale of operations and higher working capital needs. The original estimates were based on a projected turnover of ₹10,000 Lakhs for FY 2025–26, which was revised to approximately ₹14,500 Lakhs. • There is no material variation in the Capital Expenditure object except changes and/or additions to vendors, as disclosed in the Prospectus.MoreLess |
| Public IssuesAug 2025, checked by Infomerics Valuation and Rating Limited | 69.49 | Due to revision in GCP limits (from 35% to 25%) under the revised SEBI guidelines, an amount of Allocation of Rs. 278.41 Lacs out of Object 3 (i.e., General Corporate Purposes) towards funding the Company’s working capital requirements, including working capital loans and Cash Credit (CC) limits and with this reallocation, the revised total allocation for working capital now stands at Rs. 3,778.41 Lacs. Furthermore, utilization under this object has exceeded the originally estimated utilization during financial year 2025-26 and 2026-27 due to the Company’s expanded scale of operations and higher working capital requirements and the working capital estimates were initially based on a projected turnover of ₹100 crore for FY 2025–26, which has now been revised to approximately ₹145 crore. | 37.78 | 35.76 | Yes | As disclosed in the Prospectus dated 28 August 2025, the original objects of the issue were Capital Expenditure (CAPEX), Funding Working Capital Requirements, General Corporate Purposes (GCP) and Unidentified Acquisition. During the quarter ended September 30 2025 andDecember31 2025 and March 31, 2026, certain modifications and reallocations were made in the utilization of IPO proceeds. Subsequently, the shareholders approved and ratified the revised utilization and reallocation of funds through a Special Resolution passed at the Extra-Ordinary General Meeting of the Members held on 12 February 2026. Accordingly: • An amount of ₹278.41 lakhs was reallocated from General Corporate Purposes to Funding Working Capital Requirements, resulting in the revised allocation for working capital requirements increasing from ₹3500 Lakhs to ₹3778.41Lakhs. • The allocation towards General Corporate Purposes and Unidentified Acquisitionwas revised from ₹2015.87 Lakhs to ₹1737.46Lakhs and shall now be utilized only towards General Corporate Purposes within the revised regulatory limits. No unidentified acquisition shall be undertaken using the IPO proceeds. • • The Company has also revised the deployment timeline of funds under General Corporate Purposes. The entire balance amount was originally expected to be utilized within FY 2025–26; however, the remaining balance of Rs. 123.25 Lakhs shall now be utilized during FY 2026–27. • Further, the utilization towards working capital requirements increased due to expansion in the scale of operations and higher working capital needs. The original estimates were based on a projected turnover of ₹10,000 Lakhs for FY 2025–26, which was revised to approximately ₹14,500 Lakhs. • There is no material variation in the Capital Expenditure object except changes and/or additions to vendors, as disclosed in the Prospectus.MoreLess |
| Public IssuesAug 2025, checked by Infomerics Valuation and Rating Limited | 69.49 | Due to revision in GCP limits (from 35% to 25%) under the revised SEBI guidelines, the funds allocated for Object 3 (Unidentified Acquisition and General Corporate Purposes) will to be utilized for GCP only, now restricted to 25% of the total IPO proceeds. Any amount excess of GCP Limit will be transferred towards meeting the Company’s working capital requirements. No unidentified acquisition will be undertaken using the IPO proceeds. Furthermore, the allocation of Rs. 278.41 Lacs from Object 3 to Object 2 for funding the Company’s working capital requirements, including working capital loans and Cash Credit Limit. With this reallocation, the revised total allocation for General Corporate Purposes stands at Rs. 1,737.46 Lacs. Further, while the utilization of these funds was initially projected over FY 2025–26 and FY 2026–27, it was subsequently expected that the entire allocation would be deployed within FY 2025–26. However, the balance amount shall now be utilized during the current financial year 2026–27. | 17.37 | 16.14 | Yes | As disclosed in the Prospectus dated 28 August 2025, the original objects of the issue were Capital Expenditure (CAPEX), Funding Working Capital Requirements, General Corporate Purposes (GCP) and Unidentified Acquisition. During the quarter ended September 30 2025 andDecember31 2025 and March 31, 2026, certain modifications and reallocations were made in the utilization of IPO proceeds. Subsequently, the shareholders approved and ratified the revised utilization and reallocation of funds through a Special Resolution passed at the Extra-Ordinary General Meeting of the Members held on 12 February 2026. Accordingly: • An amount of ₹278.41 lakhs was reallocated from General Corporate Purposes to Funding Working Capital Requirements, resulting in the revised allocation for working capital requirements increasing from ₹3500 Lakhs to ₹3778.41Lakhs. • The allocation towards General Corporate Purposes and Unidentified Acquisitionwas revised from ₹2015.87 Lakhs to ₹1737.46Lakhs and shall now be utilized only towards General Corporate Purposes within the revised regulatory limits. No unidentified acquisition shall be undertaken using the IPO proceeds. • • The Company has also revised the deployment timeline of funds under General Corporate Purposes. The entire balance amount was originally expected to be utilized within FY 2025–26; however, the remaining balance of Rs. 123.25 Lakhs shall now be utilized during FY 2026–27. • Further, the utilization towards working capital requirements increased due to expansion in the scale of operations and higher working capital needs. The original estimates were based on a projected turnover of ₹10,000 Lakhs for FY 2025–26, which was revised to approximately ₹14,500 Lakhs. • There is no material variation in the Capital Expenditure object except changes and/or additions to vendors, as disclosed in the Prospectus.MoreLess |